Clinical Trials Directory

Trials / Completed

CompletedNCT01219608

Iranian Intensive Care Unit (ICU) Glutamine Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Shahid Beheshti University of Medical Sciences · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

This is a double-blinded placebo-controlled block randomized study in intensive care patients comparing enteral glutamine supplementation to placebo. The hypothesis is an improvement of clinical and paraclinical outcomes. The primary endpoint is Infection Probability Score (IPS) and Systemic Inflammatory Response Syndrome (SIRS). Anthropometric measures and serum inflammatory mediators will be compared.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTGlutamine 0.5 g/kg/dayGlutamine 0.5 g/kg/day
DIETARY_SUPPLEMENTGlutamine 1 g/kg/dayGlutamine 1 g/kg/day
DIETARY_SUPPLEMENTEnteral NutritionOrdinary Enteral Nutrition

Timeline

Start date
2010-01-01
Primary completion
2011-06-01
Completion
2011-06-01
First posted
2010-10-13
Last updated
2011-06-14

Locations

1 site across 1 country: Iran

Source: ClinicalTrials.gov record NCT01219608. Inclusion in this directory is not an endorsement.

Iranian Intensive Care Unit (ICU) Glutamine Study (NCT01219608) · Clinical Trials Directory